Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Effect of biological therapy on work participation in patients with ankylosing spondylitis: a systematic review.

van der Burg LR, Ter Wee MM, Boonen A.

Ann Rheum Dis. 2012 Dec;71(12):1924-33. doi: 10.1136/annrheumdis-2012-201914. Epub 2012 Sep 6. Review.

PMID:
22956595
2.

The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review.

ter Wee MM, Lems WF, Usan H, Gulpen A, Boonen A.

Ann Rheum Dis. 2012 Feb;71(2):161-71. doi: 10.1136/ard.2011.154583. Epub 2011 Oct 13. Review.

PMID:
21998122
3.
4.

Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.

van der Heijde D, Han C, DeVlam K, Burmester G, van den Bosch F, Williamson P, Bala M, Han J, Braun J.

Arthritis Rheum. 2006 Aug 15;55(4):569-74.

5.

[The role of biologic agents in the therapy of ankylosing spondylitis].

Géher P, Nagy MB, Péntek M, Tóth E, Brodszky V, Gulácsi L.

Orv Hetil. 2006 Jul 2;147(26):1203-13. Review. Hungarian.

PMID:
16898082
6.

Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials.

Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L.

Ann Rheum Dis. 2010 Oct;69(10):1756-61. doi: 10.1136/ard.2008.098822. Epub 2009 Jul 28. Review. Erratum in: Ann Rheum Dis. 2012 Aug;71(8):1434.

PMID:
19640854
7.

Biologic therapies in the spondyloarthritis: new opportunities, new challenges.

Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J.

Curr Opin Rheumatol. 2003 Jul;15(4):394-407. Review.

PMID:
12819466
8.

The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.

Barkham N, Kong KO, Tennant A, Fraser A, Hensor E, Keenan AM, Emery P.

Rheumatology (Oxford). 2005 Oct;44(10):1277-81. Epub 2005 Aug 16.

PMID:
16105913
9.

Etanercept: new indication. For ankylosing spondylitis: another option.

[No authors listed]

Prescrire Int. 2005 Jun;14(77):92-3.

PMID:
15981387
10.

Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.

Braun J, McHugh N, Singh A, Wajdula JS, Sato R.

Rheumatology (Oxford). 2007 Jun;46(6):999-1004. Epub 2007 Mar 27.

PMID:
17389658
11.

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.

Boonen A, van der Heijde D, Severens JL, Boendermaker A, Landewé R, Braun J, Brandt J, Sieper J, van der Linden S.

Ann Rheum Dis. 2006 Feb;65(2):201-8. Epub 2005 Jul 13.

12.
13.

Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review.

Boonen A, de Vet H, van der Heijde D, van der Linden S.

J Rheumatol. 2001 May;28(5):1056-62. Review.

PMID:
11361189
14.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

15.

Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.

Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC Jr.

J Rheumatol. 2005 Oct;32(10):1911-7.

PMID:
16206346
16.

Infliximab: in ankylosing spondylitis.

Robinson DM, Keating GM.

Drugs. 2005;65(9):1283-91; discussion 1292-4. Review.

PMID:
15916451
17.

Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.

Saougou I, Markatseli TE, Voulgari PV, Drosos AA.

Joint Bone Spine. 2010 Jul;77(4):325-9. doi: 10.1016/j.jbspin.2010.02.014. Epub 2010 May 8.

PMID:
20452801
18.
19.

Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.

Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J.

Rheumatology (Oxford). 2005 Mar;44(3):342-8. Epub 2004 Nov 23. Erratum in: Rheumatology (Oxford). 2005 Apr;44(4):569.

PMID:
15561737
20.

The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.

Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ.

Health Technol Assess. 2009 Sep;13(41):1-190, 215-357, iii-iv. doi: 10.3310/hta13410. Review.

Supplemental Content

Support Center